Search Result

Results for "

Proton+Pump

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Proton Pump (92) ABA Receptor (3) Akt (2) Apoptosis (31) Atg8/LC3 (11) Autophagy (21) Bacterial (49) COX (2) Cuproptosis (2) Cytochrome P450 (11) Drug Intermediate (2) Drug Metabolite (9) Endogenous Metabolite (3) Environmental Pollutants (2) ERK (2) Exosomes (9) Fungal (2) Interleukin Related (11) Isotope-Labeled Compounds (25) Na+/K+ ATPase (12) NF-κB (2) Phospholipase (4) Reference Standards (20) TNF Receptor (11) TOPK (5)
By Research Areas:	Cancer (59) Cardiovascular Disease (1) Endocrinology (13) Infection (23) Inflammation/Immunology (63) Metabolic Disease (28) Neurological Disease (1)

By Targets:

Proton Pump (92)

ABA Receptor (3)

Akt (2)

Apoptosis (31)

Atg8/LC3 (11)

Autophagy (21)

Bacterial (49)

COX (2)

Cuproptosis (2)

Cytochrome P450 (11)

Drug Intermediate (2)

Drug Metabolite (9)

Endogenous Metabolite (3)

Environmental Pollutants (2)

ERK (2)

Exosomes (9)

Fungal (2)

Interleukin Related (11)

Isotope-Labeled Compounds (25)

Na+/K+ ATPase (12)

NF-κB (2)

Phospholipase (4)

Reference Standards (20)

TNF Receptor (11)

TOPK (5)

By Research Areas:

Cancer (59)

Cardiovascular Disease (1)

Endocrinology (13)

Infection (23)

Inflammation/Immunology (63)

Metabolic Disease (28)

Neurological Disease (1)

106

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Proton Pump

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0113

Omeprazole 5+ Cited Publications H 16868	Na+/K+ ATPase Proton Pump Bacterial Cytochrome P450 Apoptosis Autophagy Atg8/LC3 TNF Receptor Interleukin Related	Infection Neurological Disease Inflammation/Immunology Cancer
Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a *proton pump* inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-13662

Lansoprazole 3 Publications Verification AG-1749	Exosomes Proton Pump Bacterial Phospholipase	Inflammation/Immunology Cancer
Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-100560

Abscisic acid 3 Publications Verification (S)-(+)-Abscisic acid; ABA	Environmental Pollutants Endogenous Metabolite ABA Receptor Proton Pump	Metabolic Disease
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits *proton pump* (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-17021

Esomeprazole 3 Publications Verification (S)-Omeprazole; (-)-Omeprazole	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole ((S)-Omeprazole) is a potent and orally active *proton pump* inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-15295

Vonoprazan Fumarate 5+ Cited Publications TAK-438	Proton Pump	Metabolic Disease Cancer
Vonoprazan Fumarate (TAK-438), a *proton pump* inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-B0572

Zinc Pyrithione Maximum Cited Publications 12 Publications Verification	Environmental Pollutants Bacterial Cuproptosis Proton Pump Fungal	Infection Metabolic Disease
Zinc Pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump . Zinc Pyrithione is also a copper ionophore that delivers copper into cells and is a useful tool for studying cuproptosis .

HY-13662B

(R)-Lansoprazole 2 Publications Verification Dexlansoprazole	Exosomes Proton Pump	Inflammation/Immunology Cancer
(R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-100007

Vonoprazan 5+ Cited Publications TAK-438 free base	Proton Pump Bacterial	Endocrinology Cancer
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-B0656

Rabeprazole 5 Publications Verification LY307640	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17507

Pantoprazole 4 Publications Verification BY1023; SKF96022	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (BY10232) is an orally active and potent *proton pump* inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-B0656A

Rabeprazole sodium 5 Publications Verification LY307640 sodium	Proton Pump Apoptosis Bacterial	Inflammation/Immunology Cancer
Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17023

Esomeprazole sodium 2 Publications Verification (S)-Omeprazole sodium; (-)-Omeprazole sodium	Exosomes Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active *proton pump* inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0113A

Omeprazole sodium 5+ Cited Publications H 16868 sodium	Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3	Infection Inflammation/Immunology
Omeprazole (H 16868) sodium is an orally active H ⁺,K ⁺-ATPase inhibitor and a *proton pump* inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .

HY-109079A

Abeprazan hydrochloride DWP14012 hydrochloride; Fexuprazan hydrochloride	Proton Pump	Metabolic Disease
Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H ⁺, K ⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .

HY-109079

Abeprazan DWP14012; Fexuprazan	Proton Pump	Metabolic Disease
Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H ⁺, K ⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .

HY-17421

Tenatoprazole TU-199	Proton Pump	Infection Inflammation/Immunology
Tenatoprazole (TU-199) is an orally active imidazopyridine-based *proton pump* inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H ⁺/K ⁺-ATPase activity with an IC₅₀ of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .

HY-17507B

Pantoprazole sodium hydrate 4 Publications Verification BY1023 sodium hydrate; SKF96022 sodium hydrate	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent *proton pump* inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507A

Pantoprazole sodium 4 Publications Verification BY1023 sodium; SKF96022 sodium	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole sodium (BY10232 sodium) is an orally active and potent *proton pump* inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-139557

Zastaprazan JP-1366	Proton Pump	Inflammation/Immunology
Zastaprazan (JP-1366) is a *proton pump* inhibitor and a potent potassium-competitive acid blocker. Zastaprazan can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease .

HY-139557A

Zastaprazan citrate JP-1366 citrate	Proton Pump	Inflammation/Immunology
Zastaprazan (JP-1366) citrate is a *Proton pump* inhibitor and potent potassium-competitive acid blocker. Zastaprazan citrate can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease .

HY-N7067

Revaprazan hydrochloride 2 Publications Verification	Proton Pump Bacterial COX NF-κB ERK Akt	Infection Inflammation/Immunology
Revaprazan hydrochloride is reversible *proton pump* inhibitor. Revaprazan hydrochloride can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan hydrochloride can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan hydrochloride can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer .

HY-101664

Ilaprazole IY-81149	Proton Pump TOPK	Inflammation/Immunology Cancer
Ilaprazole (IY-81149) is an orally active *proton pump* inhibitor. Ilaprazole irreversibly inhibits H ⁺/K ⁺-ATPase in a dose-dependent manner with an IC₅₀ of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .

HY-B2145

Ilaprazole sodium IY-81149 sodium	Proton Pump TOPK	Inflammation/Immunology Cancer
Ilaprazole (IY-81149) sodium is an orally active *proton pump* inhibitor. Ilaprazole sodium irreversibly inhibits H ⁺/K ⁺-ATPase in a dose-dependent manner with an IC₅₀ of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .

HY-118283

5-Hydroxylansoprazole 1 Publications Verification AG1908	Proton Pump	Metabolic Disease
5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric *proton-pump* inhibitor and is effective in the treatment of various peptic diseases .

HY-100560S

Abscisic acid-d6 (S)-(+)-Abscisic acid-d₆; ABA-d₆	Proton Pump Isotope-Labeled Compounds ABA Receptor	Metabolic Disease
Abscisic acid-d₆ is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H ⁺-ATPase) .

HY-17021B

Esomeprazole potassium salt 2 Publications Verification (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-13662C

(S)-Lansoprazole Levolansoprazole	Proton Pump Phospholipase Bacterial Exosomes	Inflammation/Immunology
(S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-100560R

Abscisic acid (Standard) (S)-(+)-Abscisic acid (Standard); ABA (Standard)	Reference Standards Endogenous Metabolite Proton Pump ABA Receptor	Metabolic Disease
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-B0113R

Omeprazole (Standard) H 16868 (Standard)	Reference Standards Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3	Infection Metabolic Disease Cancer
Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a *proton pump* inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-400540

Padoprazanum Padoprazan	Proton Pump	Inflammation/Immunology
Padoprazanum (Padoprazan) is a *Proton Pump* inhibitor .

HY-100007A

Vonoprazan hydrochloride 5+ Cited Publications TAK-438 hydrochloride	Proton Pump Bacterial	Infection Endocrinology Cancer
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .

HY-Z2337

Rabeprazole sulfone	Drug Intermediate	Others
Rabeprazole sulfone is a metabolite of the proton pump inhibitor Rabeprazole and is an impurity reference for Rabeprazole .

HY-13662S

Lansoprazole-d4 AG-1749-d₄	Proton Pump Bacterial	Inflammation/Immunology Cancer
Lansoprazole-d₄ (AG-1749-d₄) is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid .

HY-17021A

Esomeprazole magnesium salt (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt	Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S1

Esomeprazole-d3 (S)-Omeprazole-d₃; (-)-Omeprazole-d₃	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology Endocrinology Cancer
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021R

Esomeprazole (Standard) (S)-Omeprazole (Standard); (-)-Omeprazole (Standard)	Reference Standards Proton Pump Bacterial	Inflammation/Immunology Endocrinology Cancer
Esomeprazole (Standard) is the analytical standard of Esomeprazole. This product is intended for research and analytical applications. Esomeprazole ((S)-Omeprazole) is a potent and orally active *proton pump* inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656AS

Rabeprazole-d4 sodium LY307640-d4 sodium	Isotope-Labeled Compounds Proton Pump Apoptosis	Inflammation/Immunology Cancer
Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-121851

Revaprazan SB 641257	Proton Pump Bacterial COX NF-κB ERK Akt	Infection Inflammation/Immunology
Revaprazan (SB 641257) is reversible *proton pump* inhibitor. Revaprazan can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer .

HY-17507AR

Pantoprazole sodium (Standard) BY1023 sodium (Standard); SKF96022 sodium (Standard)	Reference Standards Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent *proton pump* inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-19223

Pumaprazole BY-841	Proton Pump	Inflammation/Immunology
Pumaprazole is a reversible *proton pump* antagonist.

HY-W016033

Pantoprazole sulfide	Drug Metabolite Proton Pump	Metabolic Disease
Pantoprazole sulfide is a metabolite of Pantoprazole (HY-17507), which is a proton-pump inhibitor .

HY-17023R

Esomeprazole sodium (Standard) (S)-Omeprazole sodium (Standard); (-)-Omeprazole sodium (Standard)	Reference Standards Exosomes Proton Pump Bacterial	Endocrinology Cancer
Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium). This product is intended for research and analytical applications. Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active *proton pump* inhibitor. Esomeprazole reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-15295R

Vonoprazan Fumarate (Standard) TAK-438 (Standard)	Proton Pump Reference Standards	Metabolic Disease Cancer
Vonoprazan (Fumarate) (Standard) is the analytical standard of Vonoprazan (Fumarate). This product is intended for research and analytical applications. Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-400540A

Padoprazanum fumarate	Proton Pump	Inflammation/Immunology
Padoprazanum (Padoprazan) fumarate is a *Proton Pump* inhibitor .

HY-19865

Azeloprazole sodium	Proton Pump	Inflammation/Immunology
Azeloprazole sodium is a potent *proton pump* inhibitor (PPI). Azeloprazole sodium can be used for gastroesophageal reflux disease (GERD) research .

HY-17507E

S-Pantoprazole sodium trihydrate	Proton Pump Bacterial	Infection
S-Pantoprazole (sodium trihydrate) is related to Pantoprazole (HY-17507) that plays an important roles in gastric acid secretion disorder-related diseases, or as *proton pump* inhibitor .

HY-13662A

Lansoprazole sodium 3 Publications Verification AG-1749 sodium	Exosomes Proton Pump Phospholipase Bacterial	Inflammation/Immunology
Lansoprazole sodium (AG 1749 sodium) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole sodium (AG 1749 sodium) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-75424A

2-(Trifluoromethyl)cinnamic acid	Proton Pump	Inflammation/Immunology
2-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative that inhibits the *proton pump* (H ⁺/K ⁺-ATPase), thereby reducing gastric acid secretion. 2-(Trifluoromethyl)cinnamic acid also improves delayed gastric emptying and can be used in research on gastric diseases such as acute gastritis and gastric ulcers .

HY-B0572R

Zinc Pyrithione (Standard)	Reference Standards Cuproptosis Proton Pump Bacterial Fungal	Infection Metabolic Disease
Zinc Pyrithione (Standard) is the analytical standard of Zinc Pyrithione. This product is intended for research and analytical applications. Zinc Pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump . Zinc Pyrithione is also a copper ionophore that delivers copper into cells and is a useful tool for studying cuproptosis .

HY-17023S

Esomeprazole-d6 sodium (S)-Omeprazole-d6 sodium; (-)-Omeprazole-d6 sodium	Isotope-Labeled Compounds Proton Pump	Others
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

Cat. No.	Product Name

HY-L011

Membrane Transporter/Ion Channel Compound Library

2,174 compounds

Most of molecules enter or leave cells mainly via membrane transport proteins, which play important roles in several cellular functions, including cell metabolism, ion homeostasis, signal transduction, the recognition process in the immune system, energy transduction, etc. There are three major types of transport proteins, ATP-powered pumps, channel proteins and transporters. Transport proteins such as channels and transporters play important roles in the maintenance of intracellular homeostasis, and mutations in these transport protein genes have been identified in the pathogenesis of a number of hereditary diseases. In the central nervous system, ion channels have been linked to, but not limited to, many diseases such asataxias, paralyses, epilepsies, and deafness. This indicates the roles of ion channels in the initiation and coordination of movement, sensory perception, and encoding and processing of information. Ion channels are a major class of drug targets in drug development.

MCE designs a unique collection of 2,174 smal-molecule modulators that can be used for the research of Ion Channel and Membrane Transporter or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100560

Abscisic acid 3 Publications Verification (S)-(+)-Abscisic acid; ABA	Structural Classification Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Agricultural Research Microorganisms other families Animals Terpenoids Sesquiterpenes Abscisic acid Phytohormone Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite ABA Receptor Proton Pump
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits *proton pump* (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-100560R

Abscisic acid (Standard) (S)-(+)-Abscisic acid (Standard); ABA (Standard)	Structural Classification Microorganisms other families Animals Terpenoids Sesquiterpenes Plants Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Proton Pump ABA Receptor
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-113371R

2-Methylcitric acid (Standard) Methylcitric acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Omeprazole (sodium) (Standard) is the analytical standard of Omeprazole (sodium). This product is intended for research and analytical applications. Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM . Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria . Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

Species:	Human (2)
Tag:	His (1) GST (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702861

	ATP6V0D1 Protein, Human (GST) V-type proton ATPase subunit d 1; V-ATPase subunit d 1; 32 kDa accessory protein; V-ATPase 40 kDa accessory protein; V-ATPase AC39 subunit (p39); Vacuolar proton pump subunit d 1	Human	E. coli
	ATP6V0D1 Protein, Human (GST) is the recombinant human-derived ATP6V0D1, expressed by E. coli, with N-GST labeled tag.

HY-P72099

	ATP6AP2 Protein, Human (His) APT6M8 9; APT6M8-9; ATP6AP2; ATP6IP2; ATP6M8-9; ATPase H+; -transporting lysosomal accessory protein 2; ATPase H+; -transporting lysosomal-interacting protein 2; ATPase H+ transporting lysosomal accessory protein 2; ATPase; H+ transporting; lysosomal vacuolar proton pump; membrane sector associated protein M8 9;	Human	E. coli
	The multifunctional ATP6AP2 protein serves as a cellular receptor for renin and prorenin, contributing to lysosomal V-ATPase assembly and endolysosomal acidification. It participates in renin-dependent reactions, activates ERK1/2, and may enhance the catalytic efficiency of renin in the renin-angiotensin system. ATP6AP2 Protein, Human (His) is the recombinant human-derived ATP6AP2 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-100560S

Abscisic acid-d6
Abscisic acid-d₆ is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H ⁺-ATPase) .

HY-B0113S

Omeprazole-d3

1 Publications Verification

Omeprazole-d₃ (H 16868-d₃) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-B0113S3

Omeprazole-13C,d3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-13662S

Lansoprazole-d4
Lansoprazole-d₄ (AG-1749-d₄) is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid .

HY-17021S1

Esomeprazole-d3
Esomeprazole-d₃ is deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656AS

Rabeprazole-d4 sodium

Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17023S

Esomeprazole-d6 sodium
Esomeprazole-d₆ sodium is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-13662BS

(R)-Lansoprazole-d4
(R)-Lansoprazole-d₄ is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0656S

Rabeprazole-d4
Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-17507S

Pantoprazole-d6

Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-Z3421S

Vonoprazan-d3 fumarate

Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-W699907

Pantoprazole sulfide-d8
Pantoprazole sulfide-d₈ is the deuterium labeled Pantoprazole sulfide (HY-W016033). Pantoprazole sulfide is a metabolite of Pantoprazole (HY-17507), which is a proton-pump inhibitor .

HY-141776S

Omeprazole sulfide-d3
Omeprazole sulfide-d₃ is the deuterium labeled Omeprazole sulfide. Omeprazole metabolite Omeprazole sulfide (Ufiprazole) is a metabolite of Omeprazole, which is a proton pump inhibitor.

HY-W013186S

Lansoprazole sulfide-d4
Lansoprazole sulfide-d₄ is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole. Lansoprazole Sulfide is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC₅₀ values of 0.59 μM intracellularly and 0.46 μM in broth .

HY-17021S

Esomeprazole-d3 sodium
Esomeprazole-d₃ (sodium) is the deuterium labeled Esomeprazole. Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-17021S2

Esomeprazole-d3 potassium
Esomeprazole-d₃ potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active *proton pump* inhibitor and reduces acid secretion through inhibition of the H ⁺, K ⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .

HY-B0656AS2

Rabeprazole-d4 potassium

Rabeprazole-d₄ potassium is deuterated labeled Rabeprazole potassium. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-W719463

Rabeprazole sulfide-d4

Rabeprazole sulfide-d₄ is the deuterium labeled Rabeprazole Sulfide (HY-W003467). Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H+/K+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment .

HY-17507S1

Pantoprazole-d3

Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-B0656S1

Rabeprazole-13C,d3

Rabeprazole-13C,d3 is a deuterated labeled Rabeprazole . Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-B0656AS1

Rabeprazole-d3 sodium

Rabeprazole-d₃ sodium the deuterium labeled Rabeprazole sodium (HY-B0656A). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-135111S

4-Desmethoxy Omeprazole-d3

4-Desmethoxy Omeprazole-d₃ is the deuterium labeled 4-Desmethoxy Omeprazole. 4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_iof 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .

HY-B0656AS3

Rabeprazole-13C,d3 sodium

Rabeprazole- ¹³C,d₃ (sodium) (LY307640- ¹³C,d₃ (sodium)) is ¹³C labeled Rabeprazole (sodium). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H ⁺/K ⁺-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .

HY-W739793

Pantoprazole-d8 sodium

Pantoprazole-d₈ (BY1023-d₈) sodium is a deuterium labeled Pantoprazole (HY-17507). Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S2

Pantoprazole-d8

Pantoprazole-d₈ (BY1023-d₈) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S4

Pantoprazole-d4

Pantoprazole-d₄ (BY1023-d₄) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-B0113S4

Omeprazole-d3 sodium

Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole sodium (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .

HY-B0113S2

Omeprazole sulfone (methoxy-d3)

Omeprazole sulfone (methoxy-d₃) is the deuterium labeled Omeprazole sulfone. Omeprazole sulfone (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sulfone competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sulfone inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sulfone inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sulfone alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sulfone aslo has neuroprotective and antibacterial effects .

HY-B0113S5

Omeprazole-d6

Omeprazole-d₆ (H 16868-d₆) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-B0113S1

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks